Abstract
Apalutamide (Erleada (TM)) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
